Search Result

Results for "

PDE4 inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Adenosine Receptor (1) Adrenergic Receptor (1) Apoptosis (9) Autophagy (6) Bacterial (2) Calcium Channel (4) Cholinesterase (ChE) (1) Dopamine Receptor (1) Drug Intermediate (1) Drug Metabolite (1) EGFR (2) Endogenous Metabolite (15) Fungal (1) GABA Receptor (1) Histamine Receptor (3) HIV (2) Influenza Virus (1) Interleukin Related (3) Isotope-Labeled Compounds (8) JAK (1) mAChR (5) MMP (1) mTOR (2) NF-κB (2) NO Synthase (4) p38 MAPK (1) Phosphodiesterase (PDE) (167) Platelet-activating Factor Receptor (PAFR) (1) PPAR (2) RSV (5) TNF Receptor (10)
By Research Areas:	Cancer (23) Cardiovascular Disease (14) Endocrinology (14) Infection (3) Inflammation/Immunology (122) Metabolic Disease (15) Neurological Disease (33)

By Targets:

5-HT Receptor (1)

Adenosine Receptor (1)

Adrenergic Receptor (1)

Apoptosis (9)

Autophagy (6)

Bacterial (2)

Calcium Channel (4)

Cholinesterase (ChE) (1)

Dopamine Receptor (1)

Drug Intermediate (1)

Drug Metabolite (1)

EGFR (2)

Endogenous Metabolite (15)

Fungal (1)

GABA Receptor (1)

Histamine Receptor (3)

HIV (2)

Influenza Virus (1)

Interleukin Related (3)

Isotope-Labeled Compounds (8)

JAK (1)

mAChR (5)

MMP (1)

mTOR (2)

NF-κB (2)

NO Synthase (4)

p38 MAPK (1)

Phosphodiesterase (PDE) (167)

Platelet-activating Factor Receptor (PAFR) (1)

PPAR (2)

RSV (5)

TNF Receptor (10)

By Research Areas:

Cancer (23)

Cardiovascular Disease (14)

Endocrinology (14)

Infection (3)

Inflammation/Immunology (122)

Metabolic Disease (15)

Neurological Disease (33)

173

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-108623

Atizoram CP-80,633	Phosphodiesterase (PDE)	Inflammation/Immunology
Atizoram (CP-80,633), a cyclic nucleotide phosphodiesterase (PDE4) inhibitor, elevates plasma cyclic AMP levels and decreases tumor necrosis factor-α (TNFα) production in mice .

HY-155830

PDE4-IN-14	Phosphodiesterase (PDE)	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
PDE4-IN-14 (Compound 1) is a *PDE4* inhibitor that can be used in the study of PDE4-related diseases (such as inflammatory and immune diseases, cancer, and metabolic diseases, etc.) .

HY-U00410

PDE4 inhibitor intermediate 1	Drug Intermediate	Others
PDE4 inhibitor intermediate 1 is an intermediate for PDE4 inhibitor synthesis.

HY-162797

PDE4-IN-18	Phosphodiesterase (PDE) TNF Receptor Interleukin Related	Inflammation/Immunology
PDE4-IN-18 (compound 1l) is a *PDE4* inhibitor (IC₅₀=1.55 μM) with anti-inflammatory activity. PDE4-IN-18 exerts anti-inflammatory effects by reducing excessive immune cell infiltration and intestinal membrane formation, as well as reducing the mRNA expression of pro-inflammatory cytokines (such as TNF-α and IL-6) in synovial tissue. PDE4-IN-18 can be used in the study of rheumatoid arthritis and psoriasis .

HY-155692

PDE4-IN-13	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4-IN-13 is a *PDE4* inhibitor with an IC₅₀ of 1.56 μM. PDE4-IN-13 shows anti-inflammatory and antioxidant properties， and can be used for chronic obstructive pulmonary disease (COPD) research .

HY-122167

L-869298	Phosphodiesterase (PDE)	Inflammation/Immunology
L-869298 is a potent and selective *PDE4* inhibitor with an IC₅₀ of 0.5 nM for PDE4A. L-869298 shows less active against hERG potassium channel .

HY-69172

RS-25344	Phosphodiesterase (PDE)	Cardiovascular Disease Neurological Disease Inflammation/Immunology
RS-25344 is a selective inhibitor of phosphodiesterase type IV (PDE4). RS-25344 increases intracellular cAMP (cyclic adenosine phosphate) concentration by inhibiting *PDE4* activity. RS-25344 can be used in the study of inflammation, immune diseases, neurodegenerative diseases and cardiovascular diseases .

HY-19393

SCH 351591	Phosphodiesterase (PDE)	Inflammation/Immunology
SCH 351591 is a potent, selective and orally active phosphodiesterase-4 (PDE4) inhibitor with an IC₅₀ of 58 nM. SCH 351591 can inhibit all 4 PDE4 subtypes (A, B, C, and D). SCH 351591 has the potential for the asthma and chronic obstructive pulmonary disease (COPD) research .

HY-124388

PDE4-IN-20	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4-IN-20 is a selective submicromolar phosphodiesterase-4 (PDE4) inhibitor with anti-TNF-α properties. PDE4-IN-20 exhibits significant biological activity in vitro and in vivo. The mechanism of action of PDE4-IN-20 is supported by molecular modeling studies, which reveal its binding mode with PDE4. PDE4-IN-20 was optimized in further conformational analysis and showed pharmacological characteristics similar to those of known PDE4 inhibitors .

HY-W787896

PDE4-IN-25	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4-IN-25 (compound 12) is a potent inhibitor of *PDE4*，with the IC₅₀ of 0.1 μM. PDE4-IN-25 plays an important role in inflammatory diseases research .

HY-146974

PDE4-IN-9	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4-IN-9 (Compound 5j) is a potent inhibitor of *PDE4. PDE4-IN-9 exhibits lower IC₅₀* value (1.4 μM) against PDE4 than parent rolipram (2.0 μM) in in vitro enzyme assay. PDE4-IN-9 also displays good in vivo activity in animal models of asthma/COPD and sepsis induced by LPS .

HY-115871A

(Rac)-PDE4-IN-4	mAChR Phosphodiesterase (PDE)	Others
(Rac)-PDE4-IN-4 is the diastereomer mixture of PDE4-IN-4 (HY-115871). PDE4-IN-4 is a dual M3 (pIC₅₀ = 10.2) antagonist-PDE4 (pIC₅₀ = 8.8) inhibitor for the inhaled research of pulmonary diseases .

HY-147950

PDE4-IN-10	Phosphodiesterase (PDE) TNF Receptor	Inflammation/Immunology
PDE4-IN-10 (compound 7a) is a potent *PDE4* inhibitor, with an IC₅₀ of 7.01 μM for *PDE4B. PDE4-IN-10 shows selectivity, microsomal stability, inhibition of TNF-α* and no major toxicities in vitro .

HY-169258

PDE4-IN-21	Phosphodiesterase (PDE)	Metabolic Disease
PDE4-IN-21 (Compound L19) is a poetent *PDE4* inhibitor, with an IC₅₀ of 0.48 μM. PDE4-IN-21 exhibits good inhibitory activity and remarkable metabolic stability in rat liver microsomes .

HY-162583

PDE4-IN-17	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4-IN-17 (compound 4e) is a potent *PDE4* inhibitor. PDE4-IN-17 inhibits *PDE4B* and *PDE4D* with IC₅₀s of 10.0 and 15.2 nM, respectively. PDE4-IN-17 has good oral bioavailability (F=66%) and longer half-life (t_1/2=2.0 h) in SD rats .

HY-132887

PDE4-IN-3	Phosphodiesterase (PDE)	Others
PDE4-IN-3 is a novel and orally active *PDE4* inhibitor with potent inhibitory affinity (IC₅₀ = 4.2 nM).

HY-151174

PDE4-IN-12	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4-IN-12 is a potent pan-PDE4 inhibitor, with IC₅₀s of 3.5 and 15 nM for *PDE4* and PDE7, respectively (SI=2.71 and 4.27, respectively). PDE4-IN-12 shows well tolerated, can be used in study of inflammatory bowel diseases (IBDs) .

HY-150060

PDE4-IN-11	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4-IN-11 is an inhibitor of phosphodiesterase isoenzyme 4 (PDE4). PDE4-IN-11 displays highly effective bronchodilatory and anti-inflammatory properties, can be used for obstructive or inflammatory airway diseases research .

HY-108617

YM976	Phosphodiesterase (PDE)	Inflammation/Immunology
YM976 is a phosphodiesterase 4 (PDE4) inhibitor with an IC₅₀ of 2.2 nM. YM976 shows the dissociation of anti-inflammatory activities from emetic effects and inhibits the antigen-induced airway responses .

HY-172135

PDE4-IN-26	p38 MAPK Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4-IN-26 (Compound A5) is an orally active and highly selective *PDE4* inhibitor. PDE4-IN-26 has anti-inflammatory activity and can inhibit the phosphorylation of p38 MAPK. In mouse models of acute lung injury and chronic obstructive pulmonary disease, PDE4-IN-26 can improve pulmonary inflammation, injury and fibrosis, promote sputum secretion and relieve cough in mice. PDE4-IN-26 can be used for the research of lung injury-related diseases .

HY-144265

PDE4-IN-5	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4-IN-5 (compound 33a) is a potent and selective *PDE4* inhibitor (IC₅₀=3.1 nM). PDE4-IN-5 has favorable skin permeability and a well-characterized binding mechanism. Anti-psoriasis effect .

HY-W186242

PDE4-IN-16	Phosphodiesterase (PDE)	Neurological Disease Inflammation/Immunology
PDE4-IN-16 (compound 27) is a *PDE4* inhibitor with an IC₅₀ value of 3.61 μM. PDE4-IN-16 can be used for the research of inflammatory diseases and central nervous system (CNS) disorders involving elevated levels of cytokines .

HY-159654

PDE4-IN-19	Phosphodiesterase (PDE)	Others
PDE4-IN-19 (compound 1) is a *PDE4* inhibitor, with IC₅₀ values of <10 nM and 10-100 nM for PDE4B1 and PDE4D3, respectively .

HY-161381

PDE4-IN-15	Phosphodiesterase (PDE) TNF Receptor	Inflammation/Immunology
PDE4-IN-15 (compound 7b-1) is an inhibitor of *PDE4* (IC₅₀ = 0.17 μM) and has anti-TNF-α activity (EC₅₀ = 0.19 μM). PDE4-IN-15 has a good skin permeability .

HY-10978

Crisaborole 3 Publications Verification AN-2728; PF-06930164	Phosphodiesterase (PDE)	Inflammation/Immunology Cancer
Crisaborole (AN-2728) is a potent inhibitor of *PDE4* and cytokine release; inhibit PDE4 with an IC₅₀ of 0.49 μM.

HY-115913

PDE4-IN-6	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4-IN-6 is a potent, safe and moderately selective *PDE4* inhibitor with IC₅₀s of 0.125 and 0.43 µM for PDE4B and PDE4D, respectively. PDE4-IN-6 can downregulate the expression level of TNF-α and IL-6. PDE4-IN-6 has potent immunomodulatory activity thereby its potential against rheumatoid arthritis. Anti-inflammatory and anti-arthritic effects .

HY-160864

Torbafylline HWA 448	Phosphodiesterase (PDE)	Cancer
Torbafylline is a PDE inhibitor. Torbafylline mitigates protein breakdown in rat skeletal muscle following burns by activating the PDE4/cAMP/EPAC/PI3K/Akt signaling pathway. Torbafylline suppresses the increased ubiquitin-proteasome-dependent protein degradation observed in the skeletal muscles of rats susceptible to cancer and sepsis .

HY-168212

PDE4-IN-22	Phosphodiesterase (PDE) TNF Receptor Interleukin Related	Inflammation/Immunology
PDE4-IN-22 (Compound 2e) is a *PDE4* inhibitor with an IC₅₀ value of 2.4 nM. PDE4-IN-22 exhibits anti-inflammatory activity and demonstrates significant anti-psoriatic effects in an Imiquimod (HY-B0180)-induced psoriasis mouse model .

HY-144684

PDE4-IN-8	Phosphodiesterase (PDE) Interleukin Related	Cancer
PDE4-IN-8 (Example 5) is a potent *PDE4* inhibitor with an IC₅₀ of 0.93 nM for PDE4B2.PDE4-IN-8 has little effect on IL13 (IC₅₀=4.04 nM), IL4 (IC₅₀=36.33 nM), IFNy (IC₅₀=2394 nM) .

HY-155819

M3/PDE4 modulator-1	mAChR Phosphodiesterase (PDE)	Inflammation/Immunology
M3/PDE4 modulator-1 (compound 10f) is a bifunctional molecule that is an M3 mAChR antagonist and a PDE4 inhibitor. M3/PDE4 modulator-1 (10-1000 nM/kg; iv) reduces cysteine eosinophil influx in the OVA rat model .

HY-115871

PDE4-IN-4	Phosphodiesterase (PDE) mAChR	Others
PDE4-IN-4 is a dual M3 (pIC₅₀ = 10.2) antagonist-PDE4 (pIC₅₀ = 8.8) inhibitor for the inhaled research of pulmonary diseases.

HY-161772

(S)-Gebr32a	Phosphodiesterase (PDE)	Neurological Disease
(S)-Gebr32a is a potent *PDE4* inhibitor with IC₅₀ values of 19.5, 2.1 µM for PDE4 cat; PDE4D3, respectively .

HY-147846

AChE/PDE4-IN-1	Cholinesterase (ChE) Phosphodiesterase (PDE)	Neurological Disease
AChE/PDE4-IN-1 (compound 12c) is a potent and selective dual *PDE4/AChE* inhibitor, with IC₅₀s of 0.28 μM and 1.88 μM for AChE and *PDE4D, respectively. AChE/PDE4*-IN-1 exhibits anti-neuroinflammatory effect for the research of Alzheimer's disease .

HY-169981

PDE4-IN-24	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4-IN-24 (compoud 14h) is a potent inhibitor of *PDE4D* with the IC₅₀ of 0.57 nM and >4100-fold selectivity over other PDE families. PDE4-IN-24 plays an important role in inflammatory disease .

HY-10978S

Crisaborole-d4 AN-2728-d₄; PF-06930164-d₄	Phosphodiesterase (PDE)	Inflammation/Immunology
Crisaborole-d₄ is deuterium labeled Crisaborole. Crisaborole (AN-2728) is a potent inhibitor of PDE4 and cytokine release; inhibit PDE4 with an IC50 of 0.49 μM.

HY-106137

Tofimilast	Phosphodiesterase (PDE)	Neurological Disease Inflammation/Immunology
Tofimilast is an inhibitor of Phosphodiesterase 4 (PDE4) with an IC₅₀ of 0.14 μM. Tofimilast exerts its anti-inflammatory effects by inhibiting the activity of PDE4, thereby increasing intracellular levels of cAMP .

HY-10978R

Crisaborole (Standard)	Phosphodiesterase (PDE)	Inflammation/Immunology
Crisaborole (Standard) is the analytical standard of Crisaborole. This product is intended for research and analytical applications. Crisaborole (AN-2728) is a potent inhibitor of *PDE4* and cytokine release; inhibit PDE4 with an IC₅₀ of 0.49 μM.

HY-145583

Mufemilast Hemay005	Phosphodiesterase (PDE)	Others
Mufemilast is a phosphodiesterase 4 (PDE4) inhibitor .

HY-105096

Arofylline LAS 31025	Phosphodiesterase (PDE)	Inflammation/Immunology
Arofylline is a *PDE4* inhibitor as a potential research for asthma.

HY-130786

Denbufylline BRL 30892	Phosphodiesterase (PDE)	Others Inflammation/Immunology
Denbufylline (BRL 30892) is an inhibitor of phosphodiesterase-4 (PDE4). Denbufylline is able to block the degradation of intracellular cAMP (cyclic adenosine phosphate) thereby increasing the level of intracellular cAMP, which helps regulate a variety of cellular functions. Denbufylline can be used in the study of chronic obstructive pulmonary disease (COPD), asthma and other inflammatory diseases .

HY-B0327A

Irsogladine maleate Dicloguamine maleate; MN1695	mAChR Phosphodiesterase (PDE)	Inflammation/Immunology
Irsogladine is a PDE4 inhibitor and muscarinic acetylcholine receptor binder.

HY-B0327

Irsogladine 2 Publications Verification Dicloguamine	mAChR Phosphodiesterase (PDE)	Inflammation/Immunology
Irsogladine is a PDE4 inhibitor and muscarinic acetylcholine receptor binder.

HY-16900

Rolipram 10+ Cited Publications (R,S)-Rolipram; (±)-Rolipram; ZK 62711	Phosphodiesterase (PDE) Bacterial HIV	Neurological Disease Cancer
Rolipram is a selective phosphodiesterases *PDE4* inhibitor with IC₅₀s of 3 nM, 130 nM and 240 nM for PDE4A, PDE4B, and PDE4D, respectively.

HY-100118

BW-A 78U	Phosphodiesterase (PDE)	Inflammation/Immunology
BW-A 78U is a *PDE4* inhibitor with an IC₅₀ of 3 μM.

HY-115383

Roflupram 1 Publications Verification	Phosphodiesterase (PDE)	Neurological Disease Inflammation/Immunology
Roflupram is a selective, orally active and brain-penetrant *PDE4* inhibitor, with an IC₅₀ of 26.2 nM for core catalytic domains of human PDE4. Roflupram can reverse cognitive deficits and reduce the production of pro-inflammatory factors .

HY-16900A

(R)-(-)-Rolipram 2 Publications Verification (R)-Rolipram; (-)-Rolipram	Phosphodiesterase (PDE)	Neurological Disease
(R)-(-)-Rolipram is the R-enantiomer of Rolipram. Rolipram is a selective inhibitor of phosphodiesterases *PDE4* with IC₅₀ of 3 nM, 130 nM and 240 nM for PDE4A, PDE4B, and PDE4D, respectively.

HY-100927

Ro 20-1724 Ro 20-174	Phosphodiesterase (PDE)	Neurological Disease
Ro 20-1724 (Ro 20-174) is a potent inhibitor of cAMP-specific phosphodiesterase *(PDE4/PDE IV)* with a K_i of 1930 nM. Neuroprotective effect .

HY-163606

PDE4B/D-IN-3	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4B/D-IN-3 (example 22) is a potent inhibitor of *PDE4, with IC₅₀s of 0.071 nM and 0.09 nM for PDE4B2* and *PDE4D*, respectively .

HY-163605

PDE4B/D-IN-2	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4B/D-IN-2 (example 19) is a potent inhibitor of *PDE4, with IC₅₀s of 0.023 nM and 0.066 nM for PDE4B2* and *PDE4D*, respectively .

HY-U00254

L791943	Phosphodiesterase (PDE)	Neurological Disease
L791943 is a potent, selective Phosphodiesterase-4 (PDE4) inhibitor with an IC₅₀ of 4.2 nM.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0014

Icariin Maximum Cited Publications 15 Publications Verification Ieariline	Cardiovascular Disease Flavonols Structural Classification Classification of Application Fields Anti-aging Source classification Plants Monophenols Flavonoids Phenols Epimedium brevicornu Maxim. Berberidaceae Inflammation/Immunology Disease Research Fields Cancer	Phosphodiesterase (PDE) PPAR Autophagy
Icariin is a flavonol glycoside. Icariin inhibits PDE5 and *PDE4* activities with IC₅₀s of 432 nM and 73.50 μM, respectively. Icariin also is a PPARα activator.

HY-122942

Moracin M 2 Publications Verification	Structural Classification Classification of Application Fields Source classification Phenols Polyphenols Plants Moraceae Endogenous metabolite Inflammation/Immunology Disease Research Fields Morus alba Linn.	Phosphodiesterase (PDE) Endogenous Metabolite NF-κB Autophagy
Moracin M is a phenolic component that can be isolated from Mori Cortex, is a potent phosphodiesterase-4 (PDE4) inhibitor with IC₅₀ values of 2.9, 4.5, >40, and >100 μM for PDE4D2, PDE4B2, PDE5A1, and PDE9A2, respectively. Moracin M has anti-inflammatory activity .

HY-A0027

Fenspiride hydrochloride	Classification of Application Fields Disease Research Fields Endocrinology	Histamine Receptor Phosphodiesterase (PDE)
Fenspiride, an orally active non-steroidal antiinflammatory agent, is an antagonist of H1-histamine receptor. Fenspiride inhibites phosphodiesterase 3 (PDE3), phosphodiesterase 4 (PDE4) and phosphodiesterase 5 (PDE5) activities with -log IC₅₀ values of 3.44, 4.16 and approximately 3.8, respectively. Fenspiride can be used for the research of respiratory diseases .

HY-16558

Butein 4 Publications Verification 2’,3,4,4’-tetrahydroxy Chalcone	Structural Classification Chalcones Flavonoids other families Classification of Application Fields Anti-aging Source classification Phenols Polyphenols Plants Disease Research Fields Cancer	EGFR Autophagy Apoptosis Phosphodiesterase (PDE)
Butein is a cAMP-specific PDE inhibitor with an IC₅₀ of 10.4 μM for *PDE4* . Butein is a specific protein tyrosine kinase inhibitor with IC₅₀s of 16 and 65 μM for EGFR and p60 ^c-src in HepG2 cells . Butein sensitizes HeLa cells to Cisplatin through AKT and ERK/p38 MAPK pathways by targeting FoxO3a . Butein is a SIRT1 activator (STAC).

HY-B0442

Vardenafil 2 Publications Verification	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology	Phosphodiesterase (PDE) Endogenous Metabolite
Vardenafil is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-N10317

Toddacoumalone	Structural Classification other families Classification of Application Fields Source classification Coumarins Phenylpropanoids Plants Inflammation/Immunology Disease Research Fields	Phosphodiesterase (PDE)
Toddacoumalone is a natural inhibitor of phosphodiesterase 4 (PDE4) with moderate potency and imperfect agent-like properties. Toddacoumalone has the potential for the research of inflammatory diseases such as psoriasis .

HY-N2958

Braylin	Source classification Rutaceae Plants Zanthoxylum tingoassuiba A.St.-Hil.	Phosphodiesterase (PDE)
Braylin, a coumarin, is a potent phosphodiesterase-4 (PDE4) inhibitor and is involved in anti-inflammatory and immunomodulation, which may serve as a potential target for the study of immunoinflammatory diseases .

HY-N0014R

Icariin (Standard) Ieariline (Standard)	Cardiovascular Disease Structural Classification Classification of Application Fields Anti-aging Source classification Plants Flavonoids Phenols Epimedium brevicornu Maxim. Berberidaceae Inflammation/Immunology Disease Research Fields Cancer	Phosphodiesterase (PDE) PPAR Autophagy
Icariin (Standard) is the analytical standard of Icariin. This product is intended for research and analytical applications. Icariin is a flavonol glycoside. Icariin inhibits PDE5 and *PDE4* activities with IC₅₀s of 432 nM and 73.50 μM, respectively. Icariin also is a PPARα activator.

HY-N11431

ent-Toddalolactone	Toddalia asiatica (L.) Lam. Structural Classification Source classification Rutaceae Coumarins Phenylpropanoids Plants	Others
ent-Toddalolactone is a natural compound with anti-inflammatory and anticancer activities. Ent-Toddalolactone has shown inhibitory effects on phosphodiesterase-4 (PDE4) in vitro and is a potential drug target for inhibiting asthma and chronic obstructive pulmonary disease. The activity of ent-Toddalolactone is related to its unique chemical structure, and some of its derivatives showed IC₅₀ values below 10 μM in inhibition experiments, showing high biological activity .

HY-B0442C

Vardenafil dihydrochloride	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology	Endogenous Metabolite Phosphodiesterase (PDE)
Vardenafil dihydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM respectively, while IC₅₀s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^- .

HY-B0442A

Vardenafil hydrochloride 2 Publications Verification	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology	Phosphodiesterase (PDE) Endogenous Metabolite
Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-B0442B

Vardenafil hydrochloride trihydrate 2 Publications Verification	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology	Endogenous Metabolite Phosphodiesterase (PDE)
Vardenafil hydrochloride trihydrate is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride trihydrate shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride trihydrate competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride trihydrate can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-16558R

Butein (Standard)	Structural Classification Chalcones Flavonoids other families Source classification Phenols Polyphenols Plants	EGFR Autophagy Apoptosis Phosphodiesterase (PDE)
Butein (Standard) is the analytical standard of Butein. This product is intended for research and analytical applications. Butein is a cAMP-specific PDE inhibitor with an IC50 of 10.4 μM for PDE4 . Butein is a specific protein tyrosine kinase inhibitor with IC50s of 16 and 65 μM for EGFR and p60c-src in HepG2 cells . Butein sensitizes HeLa cells to Cisplatin through AKT and ERK/p38 MAPK pathways by targeting FoxO3a . Butein is a SIRT1 activator (STAC).

HY-18252

Avanafil 1 Publications Verification TA1790	Cardiovascular Disease Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Endocrinology	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite
Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-18252R

Avanafil (Standard)	Structural Classification Natural Products Source classification Endogenous metabolite	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite
Avanafil (Standard) is the analytical standard of Avanafil. This product is intended for research and analytical applications. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-18252A

Avanafil dibenzenesulfonate TA1790 dibenzenesulfonate	Cardiovascular Disease Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Endocrinology	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite
Avanafil (TA-1790) dibenzenesulfonate is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil dibenzenesulfonate activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil dibenzenesulfonate inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil dibenzenesulfonate can be used for the research of erectile dysfunction and osteoporosis .

HY-113972R

Methyl mycophenolate (Standard)	Structural Classification Monophenols Microorganisms Marine natural products Phenols Marine microorganism	Others
Avanafil (Standard) is the analytical standard of Avanafil. This product is intended for research and analytical applications. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-B0442CR

Vardenafil (dihydrochloride) (Standard)	Structural Classification Natural Products Source classification Endogenous metabolite	Endogenous Metabolite Phosphodiesterase (PDE)
Vardenafil (dihydrochloride) (Standard) is the analytical standard of Vardenafil (dihydrochloride). This product is intended for research and analytical applications. Vardenafil dihydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM respectively, while IC50s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes - .

HY-B0442R

Vardenafil (Standard)	Structural Classification Natural Products Source classification Endogenous metabolite	Phosphodiesterase (PDE) Endogenous Metabolite
Vardenafil (Standard) is the analytical standard of Vardenafil. This product is intended for research and analytical applications. Vardenafil is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-W049735R

N,N,O-Tridesmethylvenlafaxine (Standard)	Structural Classification Monophenols Source classification Phenols Endogenous metabolite	Drug Metabolite Endogenous Metabolite
Vardenafil (dihydrochloride) (Standard) is the analytical standard of Vardenafil (dihydrochloride). This product is intended for research and analytical applications. Vardenafil dihydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM respectively, while IC50s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes - .

HY-N3945R

Glaucine (Standard)	Alkaloids Structural Classification other families Source classification Plants Isoquinoline Alkaloids Glaucium flavum Papaveraceae	Phosphodiesterase (PDE) Calcium Channel Adrenergic Receptor Dopamine Receptor Influenza Virus
Glaucine (Standard) is the analytical standard of Glaucine. This product is intended for research and analytical applications. Glaucine (O,O-Dimethylisoboldine) is an alkaloid isolated from Glaucium flavum with antitussive, bronchodilation and anti-inflammatory properties. Glaucine is a selective and orally active phosphodiesterase 4 (PDE4) inhibitor with Kis of 3.4 μM in human bronchus and polymorphonuclear leukocytes. Glaucine is also a non-selective α-adrenoceptor antagonist, a Ca2+ entry blocker, and a weak dopamine D1 and D2 receptor antagonist. Glaucine has antioxidative and antiviral activities .

HY-B0442BR

Vardenafil hydrochloride trihydrate (Standard)	Structural Classification Natural Products Source classification Endogenous metabolite	Endogenous Metabolite Phosphodiesterase (PDE)
Vardenafil (hydrochloride trihydrate) (Standard) is the analytical standard of Vardenafil (hydrochloride trihydrate). This product is intended for research and analytical applications. Vardenafil hydrochloride trihydrate is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil hydrochloride trihydrate shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride trihydrate competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride trihydrate can be used for the research of erectile dysfunction, hepatitis, diabetes - .

HY-N3945

Glaucine O,O-Dimethylisoboldine; S-(+)-Glaucine; NSC 34396	Infection Alkaloids Structural Classification other families Classification of Application Fields Source classification Plants Isoquinoline Alkaloids Glaucium flavum Inflammation/Immunology Disease Research Fields Papaveraceae	Phosphodiesterase (PDE) Calcium Channel MMP NF-κB
Glaucine (O,O-Dimethylisoboldine) is an alkaloid extracted from Glaucium flavum that possesses various activities, including cough relief, bronchodilation, anti-inflammatory effects, analgesia, antipyretic properties, and anticancer effects. Glaucine acts as a selective and orally active inhibitor of phosphodiesterase 4 (PDE4), with a K_i of 3.4 µM in human bronchial tissues and polymorphonuclear leukocytes. Glaucine induces relaxation of human isolated bronchi by antagonizing calcium channels. Additionally, Glaucine inhibits the activation of NF-κB, leading to a reduction in the expression of the MMP-9 gene, thereby suppressing the migration and invasion of breast cancer cells. Therefore, Glaucine holds potential for research in asthma and breast cancer .

HY-N3180

Norbraylin	Toddalia asiatica (L.) Lam. Structural Classification Source classification Rutaceae Coumarins Phenylpropanoids Plants	Phosphodiesterase (PDE)
Norbraylin, a natural prenylated coumarin, is a *PDE4D2* inhibitor with an IC₅₀ value of 7.15 μM .

HY-163777

Talaroterphenyl A	Structural Classification Monophenols Microorganisms Source classification Phenols	Phosphodiesterase (PDE)
Talaroterphenyl A (compound 1) is a p-terphenyl derivative present in the mangrove sediment-derived fungus Talaromyces sp. SCSIO 41412, which exhibits phosphodiesterase 4 (PDE4) inhibitory activity (IC₅₀=1.2 μM). Talaroterphenyl A also exhibits anti-inflammatory and anti-fibrotic activities, significantly reducing the mRNA levels of pro-inflammatory cytokines IL-6, TNF-α, and IL-1β .

HY-121162

Mesembrine (+)-Mesembrine	Alkaloids other families Pyrrole Alkaloids Source classification Plants	5-HT Receptor Phosphodiesterase (PDE)
Mesembrine ((+)-Mesembrine) a main alkaloid that features an aryloctahydroindole skeleton. Mesembrine is a 5-HT transporter inhibitor with a K_i of 1.4 nM. Mesembrine also inhibits phosphodiesterase 4B (PDE4B) with an IC₅₀ of 7.8 μM .

Cat. No.	Product Name	Chemical Structure

HY-10978S

Crisaborole-d4
Crisaborole-d₄ is deuterium labeled Crisaborole. Crisaborole (AN-2728) is a potent inhibitor of PDE4 and cytokine release; inhibit PDE4 with an IC50 of 0.49 μM.

HY-12085S

Apremilast-d5
Apremilast-d₅ is a deuterium labeled Apremilast. Apremilast is an orally available inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4) with an IC50 of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC50 of 104 nM[1].

HY-15455S1

Roflumilast-d4 N-Oxide
Roflumilast-d₄ N-Oxide is the deuterium labeled Roflumilast. Roflumilast is a selective PDE4 inhibitor with IC50s of 0.7, 0.9, 0.7, and 0.2 nM for PDE4A1, PDEA4, PDEB1, and PDEB2, respectively, without affecting PDE1, PDE2, PDE3 or PDE5 isoenzymes from various cells[1][2].

HY-12085S1

Apremilast-d8
Apremilast-d₈ (CC-10004-d₈) is deuterium labeled Apremilast. Apremilast (CC-10004) is an orally available inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4) with an IC₅₀ of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC₅₀ of 104 nM .

HY-12085S3

Apremilast-d3
Apremilast-d₃ (CC-10004-d₃) is deuterium labeled Apremilast. Apremilast (CC-10004) is an orally available inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4) with an IC₅₀ of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC₅₀ of 104 nM .

HY-15455S2

Roflumilast-d3
Roflumilast-d₃ is deuterium labeled Roflumilast. Roflumilast is a selective PDE4 inhibitor with IC50s of 0.7, 0.9, 0.7, and 0.2 nM for PDE4A1, PDEA4, PDEB1, and PDEB2, respectively, without affecting PDE1, PDE2, PDE3 or PDE5 isoenzymes from various cells.

HY-15455S

Roflumilast-d4
Roflumilast-d₄ is the deuterium labeled Roflumilast. Roflumilast is a selective PDE4 inhibitor with IC50s of 0.7, 0.9, 0.7, and 0.2 nM for PDE4A1, PDEA4, PDEB1, and PDEB2, respectively, without affecting PDE1, PDE2, PDE3 or PDE5 isoenzymes from various cells[1][2].

HY-108974S

Drotaverine-d10 hydrochloride

Drotaverine-d₁₀ (hydrochloride) is the deuterium labeled Drotaverine hydrochloride. Drotaverine hydrochloride is a type 4 cyclic nucleotide phosphodiesterase (PDE4) inhibitor and an L-type voltage-dependent calcium channel (L-VDCC) blocker, blocks the degradation of 3',5'-cyclic adenosine monophosphate. Drotaverine hydrochloride exhibits in vivo antispasmodic efficacy without anticholinergic effects[1][2].

HY-B0442S

Vardenafil-d5

Vardenafil-d₅ is deuterium labeled Vardenafil. Vardenafil is a selective, orally active, potent inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil shows selectivity over PDE1 (180 nM), PDE6 (11 nM), PDE2, PDE3, and PDE4 (>1000 nM). Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil can be used for the research of erectile dysfunction[1][2].

HY-A0027AS

Fenspiride-d5

Fenspiride-d₅ is the deuterium labeled Fenspiride. Fenspiride, an orally active non-steroidal antiinflammatory agent, is an antagonist of H1-histamine receptor. Fenspiride inhibites phosphodiesterase 3 (PDE3), phosphodiesterase 4 (PDE4) and phosphodiesterase 5 (PDE5) activities with -log IC50 values of 3.44, 4.16 and approximately 3.8, respectively. Fenspiride can be used for the research of respiratory diseases[1][2][3].

HY-B0442AS

Vardenafil-d5 hydrochloride

Vardenafil-d₅ hydrochloride is deuterated labeled Vardenafil hydrochloride (HY-B0442A). Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-18252S1

Avanafil-13C5,15N,d2

Avanafil- ¹³C₅, ¹⁵N,d₂ is ¹⁵N and deuterated labeled Avanafil (HY-18252). Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks